Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Clin Cancer Res. 2009 Nov 17;15(23):7299–7308. doi: 10.1158/1078-0432.CCR-09-1745

Figure 4.

Figure 4

In-vivo efficacy assessment of various treatments in H1299 lung cancer xenografts in mice. Key: A) Vehicle control (PBS); B) weekly intravenous treatment; and C) single intratumoral treatment. The mice were administered with docetaxel, deslorelin-docetaxel conjugate (D-D), Flt23k-NP, RGD-Flt23k-NP, or D-D + RGD-Flt23k-NP either intravenously or intratumorally. Control groups received PBS alone intravenously. The solid arrows and days indicate the days when intravenous treatments were administered. Data are expressed as mean ± standard deviation for n = 6 mice.